Diana Zahn

Using magnetic nanoparticles (MNPs) for extracorporeal heating applications results in higher field strength and, therefore, particles of higher coercivity can be used, compared to intracorporeal applications. In this study, we report the synthesis and characterization of barium hexa-ferrite (BaFe₁₂O₁₉) nanoparticles as potential particles for magnetic heating. Using a precipitation method followed by high-temperature calcination, we first studied the influence of varied synthesis parameters on the particles’ properties. Second, the iron-to-barium ratio (Fe/Ba = r) was varied between 2 and 12. Vibrating sample magnetometry, scanning electron microscopy and X-ray diffraction were used for characterization. A considerable influence of the calcination temperature (T_cal) was found on the resulting magnetic properties, with a decrease in coercivity (H_C) from values above 370 kA/m for T_cal = 800–1000 °C to H_C = 45–70 kA/m for T_cal = 1200 °C. We attribute this drop in H_C mainly to the formation of entirely multi-domain particles at high T_cal. For the varying Fe/Ba ratios, increasing amounts of BaFe₂O₄ as an additional phase were detected by XRD in the small r (barium surplus) samples, lowering the particles’ magnetization. A decrease in H_C was found in the increased r samples. Crystal size ranged from 47 nm to 240 nm and large agglomerates were seen in SEM images. The reported particles, due to their controllable coercivity, can be a candidate for extracorporeal heating applications in the biomedical or biotechnological field.

Using magnetic nanoparticles for extracorporeal magnetic heating applications in bio-medical technology allows higher external field amplitudes and thereby the utilization of particles with higher coercivities (H_C). In this study, we report the synthesis and characterization of high coercivity cobalt ferrite nanoparticles following a wet co-precipitation method. Particles are characterized with magnetometry, X-ray diffraction, Mössbauer spectroscopy, transmission electron microscopy (TEM) and calorimetric measurements for the determination of their specific absorption rate (SAR). In the first series, Co_xFe_3−xO₄ particles were synthesized with x = 1 and a structured variation of synthesis conditions, including those of the used atmosphere (O₂ or N₂). In the second series, particles with x = 0 to 1 were synthesized to study the influence of the cobalt fraction on the resulting magnetic and structural properties. Crystallite sizes of the resulting particles ranged between 10 and 18 nm, while maximum coercivities at room temperatures of 60 kA/m for synthesis with O₂ and 37 kA/m for N₂ were reached. Magnetization values at room temperature and 2 T (M_RT,2T) up to 60 Am²/kg under N₂ for x = 1 can be achieved. Synthesis parameters that lead to the formation of an additional phase when they exceed specific thresholds have been identified. Based on XRD findings, the direct correlation between high-field magnetization, the fraction of this antiferromagnetic byphase and the estimated transition temperature of this byphase, extracted from the Mössbauer spectroscopy series, we were able to attribute this contribution to akageneite. When varying the cobalt fraction x, a non-monotonous correlation of H_C and x was found, with a linear increase of H_C up to x = 0.8 and a decrease for x > 0.8, while magnetometry and in-field Mössbauer experiments demonstrated a moderate degree of spin canting for all x, yielding high magnetization. SAR values up to 480 W/g (@290 kHz, 69 mT) were measured for immobilized particles with x = 0.3, whit the external field amplitude being the limiting factor due to the high coercivities of our particles.

Magnetic nanoparticles (MNPs) have been widely applied as magnetic resonance imaging (MRI) contrast agents. MNPs offer significant contrast improvements in MRI through their tunable relaxivities, but to apply them as clinical contrast agents effectively, they should exhibit a high saturation magnetization, good colloidal stability and sufficient biocompatibility. In this work, we present a detailed description of the synthesis and the characterizations of europium-substituted Mn–Zn ferrite (Mn_0.6Zn_0.4Eu_xFe_2−xO₄, x = 0.00, 0.02, 0.04, 0.06, 0.08, 0.10, and 0.15, herein named MZF for x = 0.00 and EuMZF for others). MNPs were synthesized by the coprecipitation method and subsequent hydrothermal treatment, coated with citric acid (CA) or pluronic F127 (PF-127) and finally characterized by X-ray Diffraction (XRD), Inductively Coupled Plasma (ICP), Vibrating Sample Magnetometry (VSM), Fourier-Transform Infrared (FTIR), Dynamic Light Scattering (DLS) and MRI Relaxometry at 3T methods. The XRD studies revealed that all main diffraction peaks are matched with the spinel structure very well, so they are nearly single phase. Furthermore, XRD study showed that, although there are no significant changes in lattice constants, crystallite sizes are affected by europium substitution significantly. Room-temperature magnetometry showed that, in addition to coercivity, both saturation and remnant magnetizations decrease with increasing europium substitution and coating with pluronic F127. FTIR study confirmed the presence of citric acid and poloxamer (pluronic F127) coatings on the surface of the nanoparticles. Relaxometry measurements illustrated that, although the europium-free sample is an excellent negative contrast agent with a high r₂ relaxivity, it does not show a positive contrast enhancement as the concentration of nanoparticles increases. By increasing the europium to x = 0.15, r₁ relaxivity increased significantly. On the contrary, europium substitution decreased r₂ relaxivity due to a reduction in saturation magnetization. The ratio of r₂/r₁ decreased from 152 for the europium-free sample to 11.2 for x = 0.15, which indicates that Mn_0.6Zn_0.4Eu_0.15Fe_1.85O₄ is a suitable candidate for dual-mode MRI contrast agent potentially. The samples with citric acid coating had higher r₁ and lower r₂ relaxivities than those of pluronic F127-coated samples.

This paper describes the preparation and obtained magnetic properties of large single domain iron oxide nanoparticles. Such ferrimagnetic particles are particularly interesting for diagnostic and therapeutic applications in medicine or (bio)technology. The particles were prepared by a modified oxidation method of non-magnetic precursors following the green rust synthesis and characterized regarding their structural and magnetic properties. For increasing preparation temperatures (5 to 85 °C), an increasing particle size in the range of 30 to 60 nm is observed. Magnetic measurements confirm a single domain ferrimagnetic behavior with a mean saturation magnetization of ca. 90 Am²/kg and a size-dependent coercivity in the range of 6 to 15 kA/m. The samples show a specific absorption rate (SAR) of up to 600 W/g, which is promising for magnetic hyperthermia application. For particle preparation temperatures above 45 °C, a non-magnetic impurity phase occurs besides the magnetic iron oxides that results in a reduced net saturation magnetization.

This paper elucidates the feasibility of magnetic drug targeting to the eye by using magnetic nanoparticles (MNPs) to which pharmaceutical drugs can be linked. Numerical simulations revealed that a magnetic field gradient of 20 T m ⁻¹ seems to be promising for dragging magnetic multicore nanoparticles of about 50 nm into the eye. Thus, a targeting magnet system made of superconducting magnets with a magnetic field gradient at the eye of about 20 T m ⁻¹ was simulated. For the proof-of-concept tissue experiments presented here the required magnetic field gradient of 20 T m ⁻¹ was realized by a permanent magnet array. MNPs with an optimized multicore structure were selected for this application by evaluating their stability against agglomeration of MNPs with different coatings in water for injections, physiological sodium chloride solution and biological media such as artificial tear fluid. From these investigations, starch turned out to be the most promising coating material because of its stability in saline fluids due to its steric stabilization mechanism. To evaluate the passage of MNPs through the sclera and cornea of the eye tissues of domestic pigs ( Sus scrofa domesticus ), a three-dimensionally printed setup consisting of two chambers (reservoir and target chamber) separated by the eye tissue was developed. With the permanent magnet array emulating the magnetic field gradient of the superconducting setup, experiments on magnetically driven transport of the MNPs from the reservoir chamber into the target chamber via the tissue were performed. The resulting concentration of MNPs in the target chamber was determined by means of quantitative magnetic particle spectroscopy. It was found that none of the tested particles passed the cornea, but starch-coated particles could pass the sclera at a rate of about 5 ng mm ⁻² within 24 h. These results open the door for future magnetic drug targeting to the eye.

Magnetic microspheres (MMS) used for magnetic drug targeting consist of magnetic nanoparticles (MNP) and a pharmaceutical agent embedded in a polymeric matrix material. The application of MNP for drug targeting enables guiding the MMS to a target area, imaging the position of the MMS with magnetic particle imaging, and finally inducing drug release. As latter takes place by degradation of the MMS or diffusion through the matrix, an increase in temperature, e.g. through magnetic hyperthermia, leads to an accelerated drug release. Here, MMS consisting of poly(lactic-coglycolic) acid (PLGA) with different monomer ratios were prepared by an oil-in-water emulsion evaporation method. The model drug Camptothecin (CPT) and magnetic multicore nanoparticles (MCNP) with a high specific heating rate were embedded into the microspheres. We obtained MMS in the preferred size range of 1 to 2 μm with a concentration of MCNP of 16wt%, a drug load of about 0.5wt% and an excellent heating performance of 161 W/g_MMS. Investigations of the drug release behaviour showed an accelerated drug release when increasing the temperature from 20 °C to 37 °C or 43 °C by using a water bath. In addition, an increase in drug release of about 50% through magnetic heating of the MMS up to 44 °C compared to 37 °C was observed. By this, a magnetic hyperthermia induced CPT release from PLGA MMS is demonstrated for the very first time.